Last edition
News about "siRNA therapy "
Argo Biopharma Doses First Patient in Phase 1 siRNA Trial
Argo Biopharma has dosed the first participant in the phase I trial of BW-41012, its Factor XI-targeting siRNA therapy for preventing thromboembolic diseases.
SiRNA Therapy | 22/07/2026 | By News Bureau | 137
US FDA and EMA Accept Cemdisiran Regulatory Submissions for Generalised Myasthenia Gravis
The FDA and EMA have accepted regulatory submissions for cemdisiran to treat generalised Myasthenia Gravis (gMG). If approved, it could become the first siRNA therapy for gMG with convenient quarterly subcutaneous dosing.
SiRNA Therapy | 25/06/2026 | By News Bureau | 157
Arrowhead Pharmaceuticals Wins Australia TGA Approval for REDEMPLO
Arrowhead Pharmaceuticals receives TGA approval for REDEMPLO (plozasiran) in Australia, the first treatment for Familial Chylomicronemia Syndrome (FCS), backed by phase 3 data showing significant triglyceride reduction and lower pancreatitis risk.
SiRNA Therapy | 01/05/2026 | By News Bureau | 190
Argo Biopharma's siRNA Therapy BW-20805 Gets FDA Fast Track for HAE
Argo Biopharma has received FDA Fast Track designation for BW-20805, with an ongoing global phase-II study in adult HAE patients and primary completion expected in the second half of 2026.
SiRNA Therapy | 17/03/2026 | By News Bureau | 153
Arrowhead and Novartis Sign Global License and Collaboration Deal
Novartis secures exclusive global rights to Arrowhead’s ARO-SNCA therapy for Parkinson’s and related disorders, with Arrowhead receiving USD 200 million upfront.
SiRNA Therapy | 05/09/2025 | By Dineshwori | 287
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy